Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
NCT05984615 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1961
Last updated 2023-08-09
Summary
This was a retrospective real-world evidence cohort study.
Conditions
- BRAF Positive Metastatic Melanoma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-08
- Primary Completion
- 2022-08-24
- Completion
- 2022-08-24
Countries
- United States
Study Locations
More Related Trials
-
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
NCT03199846 ·Status: COMPLETED
-
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710 ·Status: TERMINATED ·Phase: PHASE2
-
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
NCT05171374 ·Status: UNKNOWN
-
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
NCT00139360 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
NCT01213472 ·Status: COMPLETED ·Phase: PHASE1
-
PS-341 in Treating Patients With Metastatic Malignant Melanoma
NCT00024011 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT01320085 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
NCT03728465 ·Status: TERMINATED ·Phase: PHASE2
-
RAD001 Plus Bevacizumab in Metastatic Melanoma
NCT00591734 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
NCT04835805 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Panobinostat (LBH589) in Patients With Metastatic Melanoma
NCT01065467 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
NCT01153763 ·Status: COMPLETED ·Phase: PHASE2
-
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
NCT03205722 ·Status: WITHDRAWN
-
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
NCT07091695 ·Status: COMPLETED
-
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
NCT01721746 ·Status: COMPLETED ·Phase: PHASE3
-
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
NCT05741073 ·Status: RECRUITING
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
NCT01933061 ·Status: WITHDRAWN ·Phase: PHASE2
-
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
NCT05611229 ·Status: COMPLETED
-
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
NCT02156804 ·Status: COMPLETED ·Phase: PHASE2
-
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
NCT00095953 ·Status: COMPLETED ·Phase: PHASE2